Drug Database
BI

Biosimilar ranibizumab (Epruvy)

✓ Approved

Midas Pharma · VEGFA · 单克隆抗体

什么是 Biosimilar ranibizumab?

Biosimilar ranibizumab 是一种单克隆抗体,由Midas Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名Epruvy
公司Midas Pharma
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others)
状态Approved

作用机制

分子靶点

Biosimilar ranibizumab 作用于 1 个分子靶点:

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

Biosimilar ranibizumab 针对 4 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersDiabetic retinal oedema✓ Approved
Eye disordersGlaucoma✓ Approved
Eye disordersCystoid macular oedema✓ Approved
Eye disordersNeovascular age-related macular degeneration✓ Approved

相关研究文献

PubMedActa ophthalmologica2026-11-17

Intravitreal dexamethasone implant-based versus ranibizumab-based regimens for stage 3 Coats' disease: Efficacy and complications.

Zhang Juan J, Zhang Meng M, Yang Qian Q, Chang Qing Q et al.

To compare the efficacy of intravitreal dexamethasone (DEX) implant-based regimen versus ranibizumab-based regimen for managing retinal exudation and complications in stage 3 Coats' disease. Thirty-seven eyes with stage 3 Coats' disease were enrolled and followed for 24 months: 16 received DEX implants and 21 received ranibizumab as initial treatments. Outcomes included changes in retinal exudation clocks and central foveal thickness (CFT), exudative retinal detachment (ERD) resolution, changes in best-corrected visual acuity (BCVA) and complications. The DEX implant reduced retinal exudation clocks and CFT more effectively than ranibizumab at 1, 2 and 3 months (all p < 0.05). Significantly more eyes in the DEX implant group achieved exudate absorption and complete ERD resolution within 12 months without additional surgeries (both p < 0.05). The BCVA improvement was superior in the DEX implant group than in the ranibizumab group (87.5% vs. 14.29%, p < 0.001). Elevated intraocular pressure occurred in 25.0% of DEX-treated eyes and was managed medically. Cataract surgery rates were higher in the DEX group at 12 months but comparable at 24 months. Tractional retinal detachment (TRD) and epiretinal membrane (ERM) occurred more frequently in the ranibizumab group (p = 0.003 and 0.017, respectively), and more eyes in the ranibizumab group needed additional pars plana vitrectomy by 24 months. The DEX implant group achieved superior anatomic and functional outcomes compared with the ranibizumab group for stage 3 Coats' disease, with fewer vision-threatening complications such as TRD and ERM. The DEX implant may be a promising adjuvant therapy for stage 3 Coats' disease.

PMID 43042711
阅读全文 →
PubMedCureus2026-11-17

Migraine-Related Disability, Work Productivity, and Daily Functioning Among Employed Adults: A Prospective Mixed-Methods Study.

Sunil Dutt Devika D, Kumar Harsha H HH, Humaney Nalini N, Ramachandran Akshayadharshi A et al.

Background Migraine is a common neurological disorder that can substantially affect occupational productivity, daily functioning, and health-related quality of life. This study assessed migraine-related disability and work productivity among employed adults and explored their coping strategies, workplace experiences, and perceived workplace accommodations. Methodology A prospective mixed-methods observational study was conducted among 150 employed adults aged 18-55 years with a clinical diagnosis of migraine according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3). Migraine-related disability and work productivity were assessed at baseline and at the four-month follow-up using the Migraine Disability Assessment Scale (MIDAS) and Work Productivity and Activity Impairment Questionnaire (WPAI). Semi-structured interviews were conducted with 30 purposively selected participants to explore coping strategies and workplace experiences. Results Among 150 participants, most were women (68.0%), with a mean age of 34.8 ± 7.2 years. At four-month follow-up, migraine frequency, attack duration, pain severity, migraine-related disability, and work and daily activity impairment were reduced compared with baseline. Higher migraine burden was associated with greater productivity and activity impairment. Qualitative interviews with 30 participants identified coping strategies, trigger management, workplace accommodations, psychological impact, and social support as major themes. Conclusion Migraine was associated with substantial occupational and functional impairment among employed adults. Reductions in migraine frequency, attack duration, and pain severity over four months were accompanied by lower levels of severe disability and productivity-related impairment. The qualitative findings further highlighted the relevance of individualized coping strategies and supportive workplace accommodations in managing migraine-related challenges in the workplace.

PMID 43042368
阅读全文 →
PubMedCureus2026-11-16

Visual and Anatomical Outcomes of Branch Retinal Vein Occlusion in Routine Care: A Retrospective Study of 102 Eye Records.

Bernstein Suki S, Berdejo Cora C

Background Branch retinal vein occlusion (BRVO) can cause visual loss through macular oedema. Routine-care outcomes reflect heterogeneous treatment histories and follow-up. This study evaluated visual and anatomical changes and their association in a district-hospital BRVO cohort. Methods We retrospectively analysed 102 eye records classified into 11 treatment pathways within a five-year period from January 2019 to December 2023. Visual acuity (VA), recorded in letters, and five-field average optical coherence tomography (OCT) thickness were compared between baseline and the last recorded appointment with a minimum of four weeks of follow-up. Mean changes were calculated with 95% confidence intervals (CIs). Pearson and Spearman correlations assessed the association between VA gain and OCT thickness reduction. Treatment groups were described without causal comparisons. Results Median follow-up was 23 months (interquartile range, 12-38.5; range, 2-73). Mean VA increased from 60.0 ± 17.0 to 72.3 ± 13.8 letters; mean change was 12.3 ± 16.7 letters (95% CI, 9.0-15.5). Mean five-field average OCT thickness declined from 414.5 ± 109.5 to 300.5 ± 55.7 µm; mean reduction was 113.9 ± 125.2 µm (95% CI, 89.4-138.5). Forty-two eye records (41.2%) gained at least 15 letters, and four (3.9%) lost at least 15 letters. VA gain correlated with thickness reduction (Pearson r = 0.54; 95% CI, 0.38-0.66; Spearman ρ = 0.59). Exclusion of two zero-letter baseline records yielded a mean gain of 11.8 ± 16.5 letters. The aflibercept and ranibizumab categories comprised 35 and 30 records, respectively. Conclusions Visual improvement and reduced five-field average OCT thickness were observed during routine BRVO care, with a moderate association between functional and anatomical change. Ranibizumab showed the largest mean VA gain amongst the single-agent treatment groups, exceeding the observed aflibercept. Variable follow-up, small treatment subgroups, and non-random treatment selection limit comparative interpretation. The findings support assessing vision and retinal anatomy together and do not establish superiority of any treatment pathway.

PMID 43036601
阅读全文 →
PubMedCureus2026-11-16

Immediate Implant Placement With Peri-Implant Contour Augmentation in the Maxillary Central Incisor: A Three-Year Clinical and Cone-Beam Computed Tomography Follow-Up.

Tanuja B B, Ramesh A A, Kotha Haritha H, Pavani Y Y et al.

Although immediate implant placement in the anterior maxilla can shorten the treatment timeline, it presents challenges in preserving peri-implant hard- and soft-tissue contours. We report the three-year clinical and radiographic outcome of immediate implant placement combined with peri-implant contour augmentation in the region of the maxillary right central incisor. A 20-year-old man presented two months after trauma with a non-restorable cervical fracture of the maxillary right central incisor. Clinical and cone-beam computed tomography (CBCT) evaluation demonstrated facial bone deficiency with sufficient apical and palatal bone for immediate implant placement. Following atraumatic extraction, a 4 × 14 mm implant was placed in a prosthetically driven three-dimensional position with primary stability of 35 Ncm. The peri-implant gap and facial contour were augmented using deproteinized bovine bone mineral (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and a resorbable collagen membrane. Following uneventful healing, second-stage surgery was performed at three months, followed by definitive ceramic crown placement. At the three-year follow-up, the implant remained clinically stable, with healthy peri-implant soft tissues and preserved facial contour, without signs of inflammation, infection, or mobility. CBCT demonstrated maintained bone in the crestal and mid-buccal regions, with satisfactory osseointegration and preservation of peri-implant hard-tissue support. Careful case selection, atraumatic extraction, prosthetically driven implant positioning, primary stability, and appropriate management of facial bone deficiencies are important considerations for achieving predictable outcomes.

PMID 43036423
阅读全文 →
PubMedEye (London, England)2026-11-16

Real-world outcomes following 15 years of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration.

Phan Long T LT, Broadhead Geoffrey K GK, Spooner Kimberly L KL, Fraser-Bell Samantha S et al.

To evaluate visual and anatomical outcomes in eyes with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) therapy over 15-years in a real-world setting. A retrospective cohort study was conducted. Eyes with nAMD that began ranibizumab treatment between 2006 and 2009 were assessed for eligibility which required ≥ 15 years of continuous follow-up, and no prior photodynamic therapy or earlier anti-VEGF use. A total of 1202 eyes were evaluated, of which 107 met the eligibility criteria. Medical records and corresponding optical coherence tomography scans were evaluated to assess changes from baseline in visual acuity (VA), central macular thickness (CMT), anatomic findings, injection frequency, and adverse events. Mean age was 69 ± 8.7 years and mean VA was 58.4 ± 16.6 letters at treatment initiation. At year 15, mean VA change from baseline was -8.5 letters (p < 0.001, 95% CI -13.4 to -3.6). The proportion of eyes with VA 20/40 or better was 32%, and the proportion of eyes with VA worse than or equal to 20/200 was 31%. Subretinal fibrosis was present in 43% of eyes, and macular atrophy was present in 74% of eyes, 67% of which were sub-foveal. Subretinal fibrosis, sub-foveal macular atrophy, and treatment discontinuation were each associated with final VA in multivariate analysis. Anti-VEGF therapy was associated with early anatomical improvements and long-term visual preservation in a meaningful proportion of eyes with nAMD over 15 years. Macular atrophy and fibrosis were strongly associated with poorer visual outcomes.

PMID 43035550
阅读全文 →
PubMedFrontiers in artificial intelligence2026-11-15

Navigating the Pharma 4.0 revolution: how AI-enabled applications and predictive modelling shaped pharmaceutical development in the post-pandemic era: a systematic review.

Chang Xin Yi XY, Teo Clarence C, Goh Cheong Hian CH

Pharma 4.0 is touted to make processes more efficient and resilient to unforeseen circumstances, boosting productivity, speed and accuracy of pharmaceutical systems. Besides operational stability, these technological implementations could potentially improve clinical outcomes. AI-enabled Pharma 4.0 applications and predictive modelling are utilised in pharmaceutical development for the discovery of new compounds that could potentially be used as drugs for COVID-19. This systematic review examined how contemporary Pharma 4.0 technologies have impacted pharmaceutical development in the post COVID-19 pandemic. A systematic review following the "Preferred Reporting Items for Systematic Review and Meta-Analyses" (PRISMA) method was carried out on scientific peer-reviewed literature, covering the period from 2023 to 2025. From the PubMed and Scopus databases, 593 articles were identified and 57 were included for further analysis. Performance metrics describing the reported predictive models used in research areas were identified and descriptive statistics were used to present the findings. We found that predictive models of Pharma 4.0 technologies were predominantly concentrated in early-stage drug discovery and computational research, with reported benefits of more efficient and accurate processes. Our current findings on the nonclinical performance metrics observed good use cases for drug discovery, but limited insights on the clinical applications that these recent technological developments had on the pharmacological effects. These technologies enhanced complex processes, facilitated predictive models to optimise product development in the early phase of the product life cycle.

PMID 43032471
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Biosimilar ranibizumab